Form 8-K - Current report:
SEC Accession No. 0001213900-20-038523
Filing Date
2020-11-20
Accepted
2020-11-20 17:00:42
Documents
3
Period of Report
2020-11-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea130223-8k_actiniumpharm.htm 8-K 30892
2 ACTINIUM PHARMACEUTICALS, INC. 2019 PLAN ea130223ex10-1_actiniumpharm.htm EX-10.1 74283
3 AMENDMENT TO THE ACTINIUM PHARMACEUTICALS, INC. 2019 PLAN ea130223ex10-2_actiniumpharm.htm EX-10.2 6006
  Complete submission text file 0001213900-20-038523.txt   112566
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 201333262
SIC: 2834 Pharmaceutical Preparations